Issue Date: November 7, 2011
GSK Settles With U.S. Government
GlaxoSmithKline has reached an agreement in principle with the U.S. government to resolve multiple investigations into company compliance, marketing, and selling practices. The $3 billion settlement will conclude an investigation into GSK’s marketing practices begun in 2004 by the U.S. Attorney’s Office in Colorado; the Department of Justice’s investigation of inappropriate use of a Medicaid rebate; and Justice’s probe into the marketing of the diabetes drug Avandia. “This is a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today,” says GSK CEO Andrew Witty.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society